Evidence map›Paper›PMID 42257826›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2026

Cis-3-hexen-1-ol suppresses bladder cancer progression by inducing mitophagy via the PCK2/AMPK/mTOR signaling pathway.

Jingxuan Peng, Quan Zhu, Sha Li, Boyu Xiang, Yu Han, Zhengyan Tang

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jingxuan PengDepartment of Urology, First Affiliated Hospital of Jishou University, Jishou, Hunan, 416000, China.
Quan ZhuDepartment of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
Sha LiDepartment of Burns and Plastic Surgery, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
Boyu XiangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
Yu HanDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China.
Zhengyan TangDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China. 228102114@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCis-3-hexen-1-ol is a naturally occurring green leaf volatile widely distributed in aromatic and medicinal plants. However, its antitumor activity and underlying mechanisms in bladder cancer (BLCA) remain largely unexplored.

methodsThe antitumor effects of cis-3-hexen-1-ol were evaluated using human BLCA cell lines and mouse xenograft and metastasis models. Cell proliferation, migration, invasion, mitochondrial function, and mitophagy were assessed using CCK-8, EdU incorporation, transwell assays, mitochondrial membrane potential and ROS assays, transmission electron microscopy, and immunofluorescence. Transcriptomic profiling, molecular docking, co-immunoprecipitation, immunoblotting, and in vitro kinase assays were performed to elucidate the underlying molecular mechanisms.

resultsCis-3-hexen-1-ol significantly inhibited BLCA cell proliferation, migration, and invasion in vitro and suppressed tumor growth and lung metastasis in vivo without overt toxicity. Treatment induced mitochondrial dysfunction and robust mitophagy, as evidenced by mitochondrial fragmentation, loss of membrane potential, increased mitochondrial ROS, and enhanced recruitment of autophagy markers. Mechanistically, cis-3-hexen-1-ol activated mitophagy through the PCK2/AMPK/mTOR signaling axis. Genetic silencing of PCK2 or pharmacological inhibition of autophagic flux using 3-methyladenine markedly attenuated the antitumor and pro-mitophagic effects. Notably, biochemical analyses demonstrated that PCK2 undergoes autophosphorylation and directly phosphorylates AMPK in vitro, supporting a kinase-dependent regulatory mechanism.

conclusionsThese findings identify cis-3-hexen-1-ol as a novel mitophagy-inducing phytochemical that suppresses BLCA progression via activation of the PCK2/AMPK/mTOR pathway, highlighting its potential as a natural-product lead for targeted bladder cancer therapy.

Indexed as

AMP-Activated Protein KinasesDisease ProgressionMitophagySignal TransductionTOR Serine-Threonine KinasesUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationHumansMembrane Potential, MitochondrialMiceMice, Inbred BALB CMice, NudeMitochondriaAMP-Activated Protein KinasesMTOR protein, humanTOR Serine-Threonine KinasesBladder cancerCis-3-hexen-1-olMitophagyNatural productsPCK2/AMPK/mTOR signaling

Identifiers

PMID42257826
PMCPMC13469038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.